CENTESSA PHARMACEUTICALS-ADR

CNTA14 Dec 2024
Healthcare
$16.64
-0.01 (-1.07%)
Lowest Today
$16.55
Highest Today
$17.07
Today’s Open
$16.64
Prev. Close
$16.87
52 Week High
$18.97
52 Week Low
$6.65
To Invest in CENTESSA PHARMACEUTICALS-ADR

CENTESSA PHARMACEUTICALS-ADR

Healthcare
CNTA14 Dec 2024
-0.01 (-1.07%)
1M
3M
6M
1Y
5Y
Low
$16.54
Day’s Range
High
$17.07
16.54
52 Week Low
$6.65
52-Week Range
52 Week High
$18.97
6.65
1 Day
-
1 Week
-9.54%
1 month return
-6.69%
3 month return
-0.76%
6 month return
+70.06%
1 Year return
+148.82%
3 Years return
+37.71%
5 Years return
-
10 Years return
-
Institutional Holdings
Medicxi Ventures Management (Jersey) Ltd
15.14
General Atlantic Llc
7.34
Perceptive Advisors LLC
4.76
First Light Asset Management, LLC
4.51
T. Rowe Price Associates, Inc.
3.55
Adage Capital Partners Gp LLC
3.18
Vida Ventures Advisors, LLC
2.98

Market Status

Fundamentals
Market Cap
2265.1 mln
PB Ratio
4.54
PE Ratio
0
Enterprise Value
1831.38 mln
Total Assets
360.25 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Organisation
CENTESSA PHARMACEUTICALS-ADR
Employees
76
Industry
Biotechnology
CEO
Dr. Saurabh  Saha M.D., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step